Loading...

PE anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1.2
PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE
  • XMG1.2
    PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
505807 25 µg 32€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505808 100 µg 88€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  2. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  3. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  4. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  5. Wang H, et al. 2013. J Immunol. 191:6010. PubMed
  6. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
  7. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  8. Chen Y, et al. 2020. Virol Sin. . PubMed
  9. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  10. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  11. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  12. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  13. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  14. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  15. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  16. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  17. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  18. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  19. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  20. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  21. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  22. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  23. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  24. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  25. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  26. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  27. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  28. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  29. Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed
  30. Dong L, et al. 2021. Cancer Cell. . PubMed
  31. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  32. Wang X, et al. 2018. Int Immunopharmacol. 56:249. PubMed
  33. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  34. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  35. Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed
  36. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  37. Herman JD, et al. 2021. Nat Commun. 12:6853. PubMed
  38. Galeano Niño JL, et al. 2020. J Cell Sci. . PubMed
  39. Saito S, et al. 2020. Nutrients. 12:. PubMed
  40. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  41. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  42. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  43. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  44. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  45. Koenecke C, et al. 2012. J Immunol. 189:2890. PubMed
  46. Michel M, et al. 2012. Proc Natl Acad Sci U S A. 109:17459. PubMed
  47. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  48. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  49. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  50. Kuttke M, et al. 2022. Front Immunol. 13:695576. PubMed
  51. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  52. Subbiah J, et al. 2022. NPJ Vaccines. 7:68. PubMed
  53. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  54. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  55. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  56. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  57. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  58. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  59. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  60. An J, et al. 2022. iScience. 25:103570. PubMed
  61. Han JP, et al. 2022. Sci Adv. 8:eabj6901. PubMed
  62. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  63. Wan Y, et al. 2014. Vaccine. 41:241. PubMed
  64. Sandrock I, et al. 2015. PLoS One. 10: 0145010. PubMed
  65. Koren N, et al. 2021. Cell Host Microbe. 29(2):197-209.e5. PubMed
  66. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  67. Probst P, et al. 2017. Cancer Res. 77:3644. PubMed
  68. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  69. Srey MT, et al. 2020. PLoS Negl Trop Dis. 14:e0008842. PubMed
  70. Chen D, et al. 2022. J Neuroinflammation. 19:112. PubMed
  71. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  72. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  73. Shami A, et al. 2015. Sci Rep. 5: 13904. PubMed
  74. Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed
  75. Hegde S, et al. 2020. Cancer Cell. 37(3):289-307. PubMed
  76. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  77. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  78. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  79. Cho K, Hill A 2008. J Immunol Methods. 330:137. PubMed
  80. Condotta S, et al. 2015. J Immunol. 195: 116 - 125. PubMed
  81. Satoh M, et al. 2016. Sci Rep. 6:28473. PubMed
  82. Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed
  83. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  84. Hundt M, et al. 2009. J Immunol. 183:1685. PubMed
  85. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  86. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  87. Sartorius R, et al. 2015. EMBO Mol Med. 7: 973 - 988. PubMed
  88. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  89. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  90. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  91. Yan Y, et al. 2018. JCI Insight. 3. PubMed
  92. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  93. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  94. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  95. Tian X, et al. 2022. J Cell Mol Med. 26:693. PubMed
  96. Ma Y, et al. 2013. J Immunol. 190:5588. PubMed
  97. Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed
  98. QT N, et al. 2015. Antimicrob Agents Chemother. 59: 6308-6316. PubMed
  99. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  100. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  101. Galeano Niño JL, et al. 2020. J Cell Sci. 133:00:00. PubMed
  102. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  103. Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed
  104. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  105. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  106. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
  107. Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed
  108. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  109. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  110. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  111. Ren Y, et al. 2015. Sci Rep. 5: 18099. PubMed
  112. Kraus Z, et al. 2008. J Immunol. 181:7800. PubMed
  113. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  114. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  115. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  116. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  117. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  118. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  119. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  120. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  121. Karandikar SH, et al. 2019. JCI Insight. 5. PubMed
  122. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  123. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  124. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  125. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  126. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  127. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  128. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  129. Castiglioni P, et al. 2017. PLoS Negl Trop Dis. 10.1371/journal.pntd.0005240. PubMed
  130. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  131. Roy S, et al. 2019. Front Immunol. 2.404166667. PubMed
  132. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  133. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  134. Zhang J, et al. 2018. Nature. 553:91. PubMed
  135. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  136. Li H, et al. 2021. Front Immunol. 12:739605. PubMed
  137. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  138. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  139. Miao W, et al. 2020. J Immunol. 1486:204. PubMed
  140. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  141. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  142. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  143. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  144. Johnson RM, et al. 2021. Front Immunol. 11:614697. PubMed
  145. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  146. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  147. Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
  148. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  149. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  150. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  151. Wang Y, et al. 2021. Front Immunol. 11:601601. PubMed
  152. Prakash MD, et al. 2021. PLoS One. 16:e0247492. PubMed
  153. Zhang X, et al. 2020. J Cancer. 11:648. PubMed
  154. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  155. Molgora M, et al. 2020. Cell. 182:886. PubMed
  156. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  157. Tomaru U et al. 2019. Cell reports. 26(3):639-651 . PubMed
  158. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  159. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  160. Li H, et al. 2022. iScience. 25:104481. PubMed
  161. Schmit T, et al. 2022. Cell Rep. 38:110456. PubMed
  162. Zhang X, et al. 2021. Front Pharmacol. 12:706748. PubMed
  163. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  164. Zhao K, et al. 2021. Biomed Res Int. 7619849:2020. PubMed
  165. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  166. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  167. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  168. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  169. Zheng Y, et al. 2022. Transl Res. :. PubMed
  170. Gaylo A, et al. 2013. Transpl Immunol. 20:163. PubMed
  171. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  172. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  173. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  174. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  175. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  176. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  177. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  178. Nabekura T, et al. 2020. Immunity. 96:52. PubMed
  179. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  180. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  181. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  182. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  183. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  184. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
RRID
AB_315401 (BioLegend Cat. No. 505807)
AB_315402 (BioLegend Cat. No. 505808)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 12/11/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account